Associate Professor Aaron Hansen
ATH - Associate Professor
PA Southside Clinical Unit
Journal Articles
Ng, Stephanie, Ward, Elizabeth C., Garvey, Gail, Butler, Tamara, Tesiram, Joanne, Brown, Bena, Foley, Jasmine, Packer, Rebecca and Hansen, Aaron (2025). First Nations Australians and head and neck cancer: health professionals’ priorities for improving the pathway of care. Supportive Care in Cancer, 33 (7) 624, 1-12. doi: 10.1007/s00520-025-09651-y
Aalto, Tess, Abacan, Maria, Abadi, Shirin, Aghababazadeh, Farnoosh Abbas, Abbaszadeh, Zeinab, Razak, Albiruni Abdul, Abdulsalam, Safa, Abelman, Dor David, Abolghasemi, Armita, Abraham, Anju, Abraham, Rohan, Acar, Behram C., Aguilar-Mahecha, Adriana, Ahanfeshar-Adams, Mozhdeh, Aherne, Sinead, Ahmadi, Zohreh, Shifat Ahmed, Syed A.K., Ailles, Laurie, Akbari, Mohammad Reza, Akbari, Vahid, Akhavien, Azarm, Al Bati, Rima, Al-Awar, Rima, Al-Sajee, Dhuha, Al-Saleh, Afnan, Alafiatayo, Akinola A., Alam, Aqsa, Albadine, Roula, Albano, Alexandria ... Zulfigar, Muhammad (2025). The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative. Cancer Cell, 43 (4), 587-592. doi: 10.1016/j.ccell.2025.03.014
Calvo, Emiliano, Doger, Bernard, Carles, Joan, Peer, Avivit, Sarid, David, Eigl, Bernhard J., Avadhani, Anjali, Yao, David, Lin, Vincent, Wu, Shujian, Jaiprasart, Pharavee, Loffredo, John, Tamegnon, Monelle, Xu, Weichun, Xie, Hong and Hansen, Aaron R. (2025). A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer. Oncologist, 30 (1) oyae313, 1-9. doi: 10.1093/oncolo/oyae313
Hansen, Aaron R., Gomez-Roca, Carlos A., Robbrecht, Debbie G.J., Verlingue, Loic, Italiano, Antoine, Bauman, Julie E., Steeghs, Neeltje, Prenen, Hans, Fayette, Jérôme, Spicer, James, Niu, Jiaxin, Habigt, Christin, Schneider, Meike, Evers, Stefan, Sleiman, Nassim, Dejardin, David, Ardeshir, Caroline, Schmid, Daniela, Boetsch, Christophe, Charo, Jehad, Kraxner, Anton, Teichgräber, Volker, Keshelava, Nino and Bonomi, Marcelo R. (2024). Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 30 (24), 5540-5547. doi: 10.1158/1078-0432.CCR-24-1562
Yap, Christina, Lee Aiyegbusi, Olalekan, Alger, Emily, Basch, Ethan, Bell, Jill, Bhatnagar, Vishal, Cella, David, Collis, Philip, Dueck, Amylou C., Gilbert, Alexandra, Gnanasakthy, Ari, Greystoke, Alastair, Hansen, Aaron R., Kamudoni, Paul, Kholmanskikh, Olga, King-Kallimanis, Bellinda L., Krumholz, Harlan, Minchom, Anna, O'Connor, Daniel, Petrie, Joan, Piccinin, Claire, Rantell, Khadija Rerhou, Rauz, Saaeha, Retzer, Ameeta, Rizk, Steven, Wagner, Lynne, Sasseville, Maxime, Seymour, Lesley K., Weber, Harald A. ... Peipert, John Devin (2024). Advancing patient-centric care: integrating patient reported outcomes for tolerability assessment in early phase clinical trials – insights from an expert virtual roundtable. eClinicalMedicine, 76 102838, 102838. doi: 10.1016/j.eclinm.2024.102838
Ayre, Susannah K., Johnston, Elizabeth A., Bourdaniotis, Xanthia E., Zajdlewicz, Leah, Beesley, Vanessa L., Pole, Jason D., Hansen, Aaron, Gasper, Harry, Cossio, Danica, Lock, Gemma and Goodwin, Belinda C. (2024). From many voices, one question: community co-design of a population-based qualitative cancer research study. PLoS One, 19 (8) e0309361, 1-22. doi: 10.1371/journal.pone.0309361
Hernando-Calvo, Alberto, Yang, S.Y. Cindy, Vila-Casadesús, Maria, Han, Ming, Liu, Zhihui Amy, Berman, A.K. Hal, Spreafico, Anna, Razak, Albiruni Abdul, Lheureux, Stephanie, Hansen, Aaron R., Lo Giacco, Deborah, Abbas-Aghababazadeh, Farnoosh, Matito, Judith, Haibe-Kains, Benjamin, Pugh, Trevor J., Bratman, Scott V., Aleshin, Alexey, Berche, Roger, Saavedra, Omar, Garralda, Elena, Elston, Sawako, Siu, Lillian L., Ohashi, Pamela S., Vivancos, Ana and Bedard, Philippe L. (2024). Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab. JCO Precision Oncology, 8 (8) e2400100. doi: 10.1200/PO.24.00100
Stutheit-Zhao, Eric Y., Sanz-Garcia, Enrique, Liu, Zhihui, Wong, Derek, Marsh, Kayla, Abdul Razak, Albiruni R., Spreafico, Anna, Bedard, Philippe L., Hansen, Aaron R., Lheureux, Stephanie, Torti, Dax, Lam, Bernard, Yang, Shih Yu Cindy, Burgener, Justin, Luo, Ping, Zeng, Yong, Cheng, Nicholas, Awadalla, Philip, Bratman, Scott V., Ohashi, Pamela S., Pugh, Trevor J. and Siu, Lillian L. (2024). Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors. Cancer Discovery, 14 (6), 1048-1063. doi: 10.1158/2159-8290.CD-23-1060
Griffiths, Matthew R., Pattison, David A., Latter, Melissa, Kuan, Kevin, Taylor, Stephen, Tieu, William, Kryza, Thomas, Meyrick, Danielle, Lee, Boon Quan, Hansen, Aaron, Rose, Stephen E. and Puttick, Simon G. (2024). First-in-human212Pb-PSMA–targeted α-therapy SPECT/CT imaging in a patient with metastatic castration-resistant prostate cancer. Journal of Nuclear Medicine, 65 (4), 664-664. doi: 10.2967/jnumed.123.267189
Hilton, John F., Ott, Patrick A., Hansen, Aaron R., Li, Zujun, Mathew, Matthen, Messina, Cristina H., Dave, Vimal, Ji, Xiao, Karpinich, Natalie O., Hirschfeld, Steven, Ballas, Marc and Zandberg, Dan P. (2024). INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors. Cancer Immunology, Immunotherapy, 73 (3) 44. doi: 10.1007/s00262-023-03623-z
Hansen, Aaron R., Probst, Stephan, Beauregard, Jean-Mathieu, Viglianti, Benjamin L., Michalski, Jeff M., Tagawa, Scott T., Sartor, Oliver, Tutrone, Ronald F., Oz, Orhan K., Courtney, Kevin D., Delpassand, Ebrahim S., Nordquist, Luke T., Osman, Medhat M., Chi, Kim N., Sparks, Richard, George, Noble, Hawley, Sara M., Wu, Wenting, Jensen, Jessica D. and Fleshner, Neil E. (2024). Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial. Frontiers in Oncology, 14 1483953. doi: 10.3389/fonc.2024.1483953
Conduit, Ciara, Lewin, Jeremy, Weickhardt, Andrew, Lynam, James, Wong, Shirley, Grimison, Peter, Sengupta, Shomik, Pranavan, Ganes, Parnis, Francis, Bastick, Patricia, Campbell, David, Hansen, Aaron R., Leonard, Matt, McJannett, Margaret, Stockler, Martin R., Gibbs, Peter, Toner, Guy, Davis, Ian D., Tran, Ben and Kuchel, Anna (2023). Patterns of relapse in Australian patients with clinical stage 1 testicular cancer: utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance recommendations. JCO Oncology Practice, 19 (11), 973-980. doi: 10.1200/OP.23.00191
Harrington, Kevin J., Ferris, Robert L., Gillison, Maura, Tahara, Makoto, Argiris, Athanasios, Fayette, Jérôme, Schenker, Michael, Bratland, Åse, Walker, John W. T., Grell, Peter, Even, Caroline, Chung, Christine H., Redman, Rebecca, Coutte, Alexandre, Salas, Sébastien, Grant, Cliona, De Azevedo, Sergio, Soulières, Denis, Hansen, Aaron R., Wei, Li, Khan, Tariq Aziz, Miller-Moslin, Karen, Roberts, Mustimbo and Haddad, Robert (2023). Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial. JAMA Oncology, 9 (6), 779-789. doi: 10.1001/jamaoncol.2023.0147
Lim, Emerson A., Schweizer, Michael T., Chi, Kim N., Aggarwal, Rahul, Agarwal, Neeraj, Gulley, James, Attiyeh, Edward, Greger, James, Wu, Shujian, Jaiprasart, Pharavee, Loffredo, John, Bandyopadhyay, Nibedita, Xie, Hong and Hansen, Aaron R. (2023). Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 21 (3), 366-375. doi: 10.1016/j.clgc.2023.02.010
Janse van Rensburg, Helena J., Liu, Zhihui, Watson, Geoffrey A., Veitch, Zachary W., Shepshelovich, Daniel, Spreafico, Anna, Abdul Razak, Albiruni R., Bedard, Philippe L., Siu, Lillian L., Minasian, Lori and Hansen, Aaron R. (2023). A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events. British Journal of Cancer, 129 (4), 612-619. doi: 10.1038/s41416-023-02307-w
Mittal, Abhenil, Al-Ezzi, Esmail, Li, Xuan, Moloney, Brian, Wilson, Brooke, Spiliopoulou, Pavlina, Sridhar, Srikala, Fallah-Rad, Nazanin, Chung, Peter, Hamilton, Robert James, O’malley, Martin and Hansen, Aaron R. (2023). The role of cytoreductive nephrectomy and systemic therapy in the management of tumour thrombus in patients with metastatic renal cell carcinoma. British Journal of Cancer, 128 (10), 1888-1896. doi: 10.1038/s41416-023-02166-5
Hilton, John, Gelmon, Karen, Bedard, Philippe L., Tu, Dongsheng, Xu, Hong, Tinker, Anna V., Goodwin, Rachel, Laurie, Scott A., Jonker, Derek, Hansen, Aaron R., Veitch, Zachary W., Renouf, Daniel J., Hagerman, Linda, Lui, Hongbo, Chen, Bingshu, Kellar, Deb, Li, Irene, Lee, Sung-Eun, Kono, Takako, Cheng, Brian Y. C., Yap, Damian, Lai, Daniel, Beatty, Sean, Soong, John, Pritchard, Kathleen I., Soria-Bretones, Isabel, Chen, Eric, Feilotter, Harriet, Rushton, Moira ... Cescon, David W. (2022). Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies. Nature Communications, 13 (1) 3607. doi: 10.1038/s41467-022-31199-2
Even, Caroline, Delord, Jean-Pierre, Price, Katharine A., Nakagawa, Kazuhiko, Oh, Do-Youn, Burge, Matthew, Chung, Hyun C., Doi, Toshihiko, Fakih, Marwan, Takahashi, Shunji, Yao, Lili, Jin, Fan, Norwood, Kevin and Hansen, Aaron R. (2022). Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study. European Journal of Cancer, 171, 259-268. doi: 10.1016/j.ejca.2022.05.007
Choudhury, Atish D., Higano, Celestia S., de Bono, Johann S., Cook, Natalie, Rathkopf, Dana E., Wisinski, Kari B., Martin-Liberal, Juan, Linch, Mark, Heath, Elisabeth I., Baird, Richard D., García-Carbacho, Javier, Quintela-Fandino, Miguel, Barry, Simon T., de Bruin, Elza C., Colebrook, Steve, Hawkins, George, Klinowska, Teresa, Maroj, Brijesh, Moorthy, Ganesh, Mortimer, Peter G., Moschetta, Michele, Nikolaou, Myria, Sainsbury, Liz, Shapiro, Geoffrey I., Siu, Lillian L. and Hansen, Aaron R. (2022). A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 28 (11), 2257-2269. doi: 10.1158/1078-0432.CCR-21-3087
Spira, Alexander, Hansen, Aaron R., Harb, Wael A., Curtis, Kelly K., Koga-Yamakawa, Erina, Origuchi, Makoto, Li, Zhonggai, Ertik, Bella and Shaib, Walid L. (2021). Multicenter, open-label, phase I study of DSP-7888 dosing emulsion in patients with advanced malignancies. Targeted Oncology, 16 (4), 461-469. doi: 10.1007/s11523-021-00813-6
Lacas, Benjamin, Carmel, Alexandra, Landais, Cécile, Wong, Stuart J., Licitra, Lisa, Tobias, Jeffrey S., Burtness, Barbara, Ghi, Maria Grazia, Cohen, Ezra E.W., Grau, Cai, Wolf, Gregory, Hitt, Ricardo, Corvò, Renzo, Budach, Volker, Kumar, Shaleen, Laskar, Sarbani Ghosh, Mazeron, Jean-Jacques, Zhong, Lai-Ping, Dobrowsky, Werner, Ghadjar, Pirus, Fallai, Carlo, Zakotnik, Branko, Sharma, Atul, Bensadoun, René-Jean, Ruo Redda, Maria Grazia, Racadot, Séverine, Fountzilas, George, Brizel, David, Rovea, Paolo ... Zackrisson, B. (2021). Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiotherapy and Oncology, 156, 281-293. doi: 10.1016/j.radonc.2021.01.013
Iafolla, Marco A. J, Yang, Cindy, Chandran, Vinod, Pintilie, Melania, Li, Quan, Bedard, Philippe L, Hansen, Aaron, Lheureux, Stephanie, Spreafico, Anna, Razak, Albiruni A, Hakgor, Sevan, Giesler, Amanda, Pugh, Trevor J. and Siu, Lillian L (2021). Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis. JNCI Cancer Spectrum, 5 (1) pkaa115. doi: 10.1093/jncics/pkaa115
Wells, J. Connor, Graham, Jeffrey, Beuselinck, Benoit, Bjarnason, Georg A., Donskov, Frede, Hansen, Aaron R., McKay, Rana R., Vaishampayan, Ulka, De Velasco, Guillermo, Duh, Mei S., Huynh, Lynn, Nguyen, Catherine, Zanotti, Giovanni, Ramaswamy, Krishnan, Choueiri, Toni K. and Heng, Daniel Y.C. (2020). Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 18 (4), e350-e359. doi: 10.1016/j.clgc.2019.12.007
Nason, Gregory J., Chung, Peter, Warde, Padraig, Huddart, Robert, Albers, Peter, Kollmannsberger, Christian, Booth, Christopher M., Hansen, Aaron R., Bedard, Philippe L., Einhorn, Lawrence, Nichols, Craig, Rendon, Ricardo A., Wood, Lori, Jewett, Michael A.S. and Hamilton, Robert J. (2020). Controversies in the management of clinical stage 1 testis cancer. Canadian Urological Association Journal, 14 (11). doi: 10.5489/cuaj.6722
Webster, Kimberly A., O'Connor, Mary L., Hansen, Aaron R., Kircher, Sheetal, Jim, Heather S.L., Dicker, Adam P., Janda, Monika, Ala-Leppilampi, Kari, Bingham III, Clifton O., Feliciano, Josephine, Henry, Norah Lynn, McLouth, Laurie E. Steffen and Cella, David (2020). Development of a Functional Assessment of Chronic Illness Therapy item library and primary symptom list for the assessment of patient-reported adverse events associated with immune checkpoint modulators. Journal of Cancer Metastasis and Treatment, 6, 1-14. doi: 10.20517/2394-4722.2019.38
Burtness, Barbara, Harrington, Kevin J., Greil, Richard, Soulières, Denis, Tahara, Makoto, de Castro, Gilberto, Psyrri, Amanda, Basté, Neus, Neupane, Prakash, Bratland, Åse, Fuereder, Thorsten, Hughes, Brett G. M., Mesía, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Wan Ishak, Wan Zamaniah, Hong, Ruey-Long, González Mendoza, René, Roy, Ananya, Zhang, Yayan, Gumuscu, Burak, Cheng, Jonathan D., Jin, Fan, Rischin, Danny, Lerzo, Guillermo, Tatangelo, Marcelo, Varela, Mirta, Zarba, Juan Jose, Boyer, Michael ... on behalf of the KEYNOTE-048 Investigators (2019). Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. The Lancet, 394 (10212), 1915-1928. doi: 10.1016/S0140-6736(19)32591-7
Maia, Manuel Caitano and Hansen, Aaron R. (2017). A comprehensive review of immunotherapies in prostate cancer. Critical Reviews in Oncology/Hematology, 113, 292-303. doi: 10.1016/j.critrevonc.2017.02.026
Hansen, Aaron R., Hughes, Brett G., Paul, Sanjoy, Steadman, Peter, Sommerville, Scott, Dickinson, Ian C., Walpole, Euan T., Thomson, Damien B., Mar Fan, Helen G. and Joubert, Warren L. (2016). Single institution retrospective review of perioperative chemotherapy in adult and adolescent patients with operable osteosarcoma. Asia-Pacific Journal of Clinical Oncology, 12 (2), e222-e228. doi: 10.1111/ajco.12167
Duhig, Edwina Elizabeth, Dettrick, Andrew, Godbolt, David Burleigh, Pauli, John, van Zwieten, Anthony, Hansen, Aaron Richard, Yang, Ian Anthony, Fong, Kwun Meng, Clarke, Belinda E. and Bowman, Rayleen V. (2015). Mitosis trumps T stage and proposed international association for the study of lung cancer/American thoracic society/european respiratory society classification for prognostic value in resected stage 1 lung adenocarcinoma. Journal of Thoracic Oncology, 10 (4), 673-681. doi: 10.1097/JTO.0000000000000446
Huang, Shao Hui, Xu, Wei, Waldron, John, Siu, Lillian, Shen, Xiaowei, Tong, Li, Ringash, Jolie, Bayley, Andrew, Kim, John, Hope, Andrew, Cho, John, Giuliani, Meredith, Hansen, Aaron, Irish, Jonathan, Gilbert, Ralph, Gullane, Patrick, Perez-Ordonez, Bayardo, Weinreb, Ilan, Liu, Fei-Fei and O'Sullivan, Brian (2015). Refining American joint committee on cancer/union for international cancer control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas. Journal of Clinical Oncology, 33 (8), 836-845. doi: 10.1200/JCO.2014.58.6412
Conference Papers
Hansen, Aaron Richard, Pattison, David A., Ngai, Stanley, Karmann, Anna, Walker, Amanda J., Campbell, Louise, Brady, Jasmine, Katchel, Loren, Holmes, Ingrid, Rose, Stephen E., Baronet, Meghan C., Kryza, Thomas, Vito, Alyssa, Tieu, William, Kuan, Kevin, Griffiths, Matthew R., O’Mahoney, Eoin, Latter, Melissa, Gan, Chun Loo Loo and Wyld, David (2025). Phase Ib/IIa dose escalation and expansion study of [ 212 Pb]Pb-ADVC001 in metastatic castration-resistant prostate cancer: TheraPb–phase I/II study. 2025 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 13-15 February 2025. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.5_suppl.tps275
Mak, Blossom, Tran, Ben, Thomas, Hayley, Pashankar, Farzana D., Hansen, Aaron Richard, Feldman, Darren R., Huddart, Robert A, Wheater, Matthew, Dunwoodie, Elaine, Mazhar, Danish, Lawrence, Nicola Jane, Stevanovic, Amanda Gwendolyn, Birtle, Alison Jane, Oladipo, Olabode, Wyld, David, Balagtas, Jay Michael S., Stockler, Martin R., Grimison, Peter S. and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2025). An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs). 2025 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 13-15 February 2025. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2025.43.5_suppl.tps653
Hansen, Aaron Richard, Zhang, Alison Yan, Boni, Valentina, Mantia, Charlene, Yu, Evan Y., Weickhardt, Andrew James, Robert, Marie, Gupta, Shilpa, Morales-Barrera, Rafael, Hoimes, Christopher J., Berlin, Jordan, Iyer, Gopa, Millward, Michael, Lihou, Christine Francis, Loriot, Yohan, Pouessel, Damien, Mittal, Kriti, Hill, Andrew Graham, Racca, Fabricio and Tran, Ben (2025). A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301). 2025 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 13-15 February 2025. Philadelphia, PA United States: Lippincott Williams & Wilkins. doi: 10.1200/JCO.2025.43.5_suppl.TPS904
Bourdaniotis, Xanthia E., Ayre, Susannah K., Johnston, Elizabeth (Lizzy) A., Zajdlewicz, Leah, Beesley, Vanessa L., Pole, Jason D., Hansen, Aaron, Gasper, Harry, Cossio, Danica, Lock, Gemma and Goodwin, Belinda C. (2024). How should we design study invitation materials for cancer survivorship research? Findings from a consumer consultation study. COSA's 51st Annual Scientific Meeting, Gold Coast, QLD Australia, 13–15 November 2024. Chichester, West Sussex United Kingdom: Wiley-Blackwell.
Tran, B., Boni, A., Hansen, A., Boni, V., Mantia, C., Yu, E., Weickhardt, A., Robert, M., Gupta, S., Necchi, A., Morales-Barrera, R., Hoimes, C., Berlin, J., Iyer, G., Millward, M., Burn, T., Lihou, C., Gammon, G., Rosenberg, J. and Loriot, Y. (2024). Preliminary safety and anti-tumor activity of TYRA-300, a highly selective FGFR3 inhibitor, in participants with advanced solid tumors with activating FGFR3 mutations/fusions (SURF301). 36th European-Organisation-for-Research-and-Treatment-of-Cancer / National-Cancer-Institute / American-Association-for-Cancer-Research Symposium on Molecular Targets and Cancer Therapeutics (EORTC/NCI/AACR), Barcelona, Spain, 23-25 October 2024. Oxford, United Kingdom: Elsevier. doi: 10.1016/j.ejca.2024.114978
Alshankati, Khadjah, Bruce, Jeffery P., Ohashi, Pamela S., Butler, Marcus O., Cescon, David W., Hansen, Aaron Richard, Linh Nguyen,, Tsao, Ming Sound, Haibe-Kains, Benjamin, Yu, Celeste, Sabatini, Peter, Razak, Albiruni Ryan Abdul, Spreafico, Anna, Wang, Ben X., Pugh, Trevor John, Siu, Lillian L. and Bedard, Philippe L. (2024). Comprehensive whole genome and transcriptome analysis of patients with advanced solid tumor treated with immune checkpoint inhibitor therapy in the pan-cancer cohorts from the Marathon of Hope Cancer Centres Network Study (MOHCCN). 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Philadelphia, PA United States: Lippincott Williams & Wilkins. doi: 10.1200/JCO.2024.42.16_suppl.2645
Rose, April A. N., Maxwell, Jennifer, Rousselle, Emmanuelle, Riaud, Melody, Tobin, Chantal, Mcguire, Meghan, King, Ian, Zhang, Tong, Kamil, Zaid Saeed, Pugh, Trevor J., Butler, Marcus O., Shepherd, Frances A., Bedard, Philippe L., Leighl, Natasha B., Razak, Albiruni Ryan Abdul, Hansen, Aaron Richard, Saibil, Samuel, Siu, Lillian L., Cescon, David W. and Spreafico, Anna (2024). Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Final results of the investigator-initiated phase II BEAVER trial. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Philadelphia, PA United States: Lippincott Williams & Wilkins. doi: 10.1200/JCO.2024.42.16_suppl.3104
Conduit, Ciara, Grimison, Peter S., Lewin, Jeremy Howard, Hansen, Aaron Richard, Lynam, James F., Weickhardt, Andrew James, Parente, Phillip, Campbell, David Colin, Hong, Wei, Marx, Gavin M., Heron, Orlaith Mary, Kuchel, Anna, McJannett, Margaret Mary, Cusick, Thomas, Fontela, Antoinette, Haire, Sophie O., Zlatic, Kristina, Davis, Ian D. and Ben Tran, (2023). CLIMATE: Assessing the clinical utility of miR-371a-3p as a marker of residual disease in stage 1 testicular germ cell tumour (TGCT) following orchiectomy: ANZUP 1906. Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL United States, 2-6 June 2023. Philadelphia, PA United States: Lippincott Williams & Wilkins. doi: 10.1200/JCO.2023.41.16_suppl.TPS5100
Nason, Gregory J., Wood, Lori, Huddart, Robert A., Albers, Peter, Rendon, Ricardo A., Einhorn, Lawrence H., Nichols, Craig R., Kollmannsberger, Christian, Anson-Cartwright, Lynn, Sweet, Joan, Warde, Padraig, Jewett, Michael A.S., Chung, Peter, Bedard, Philippe L., Hansen, Aaron R. and Hamilton, Robert J. (2019). A Canadian approach to the regionalization of testis cancer: A review. Canadian Urological Association. doi: 10.5489/CUAJ.6268
Hansen, A., Colosimo, M., Fong, K., Yang, I. A., Bowman, R. V., Clarke, B. E., Duhig, E. E., Maar, K. and Windsor, M. (2011). The prognostic significance of high risk features in Resected Nsclc: a single institution retrospective review. 3rd Australian Lung Cancer Conference (ALCC), Melbourne, VIC Australia, 7-9 October 2010. New York, NY United States: Elsevier.